Pharmakotherapie der Zwangsstörung

 

 Buy Article Permissions and Reprints

In der Behandlung der Zwangsstörung gilt derzeit die (kognitive) Verhaltenstherapie als Mittel der ersten Wahl. In Kombination oder im Anschluss an eine Psychotherapie ist jedoch oft der Einsatz von Medikamenten unumgänglich. Antidepressiva mit spezifisch serotonergen Wirkmechanismus haben sich dabei gut etabliert. Ihre wissenschaftliche Evidenz und ihr besonderer Einsatz bei Zwangsstörungen werden im Folgenden referiert. Aufgrund der oft schweren, therapierefraktären Verläufe der Zwangserkrankung wurden in der Vergangenheit auch viele weitere medikamentöse Strategien verfolgt – diese werden ebenfalls auf ihre empfohlene Anwendbarkeit überprüft.

• Literatur

• 1 Baumgarten HG, Grozdanovic Z. Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry 1998; 35: 13-20
  PubMedGoogle Scholar
• 2 Bogan AM, Koran LM, Chuong HW et al. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 2005; 66: 73-79
  CrossrefPubMedGoogle Scholar
• 3 Bystritsky A, Ackerman DL, Rosen RM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565-568
  CrossrefPubMedGoogle Scholar
• 4 Chamberlain SR, Blackwell AD, Fineberg NA et al. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005; 29: 399-419
  CrossrefPubMedGoogle Scholar
• 5 Cottraux J, Bouvard MA, Milliery M. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther 2005; 34: 185-192
  CrossrefPubMedGoogle Scholar
• 6 Denys D. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23: 568-575
  CrossrefPubMedGoogle Scholar
• 7 Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004; 65: 7-11
  PubMedGoogle Scholar
• 8 Denys D, Mantione M, Figee M et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2010; 67: 1061-1068
  CrossrefPubMedGoogle Scholar
• 9 DGPPN Hrsg S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. Berlin/Heidelberg: Springer; 2012
  Google Scholar
• 10 DGPPN Hrsg. S3-Leitlinie Zwangsstörungen. Im Internet: http://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/kurzversion-leitlinien/S3-Leitlinie_Zwangsst%C3%B6rungen_lang.pdf ); Stand: 14.05.2013
  PubMed
• 11 Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005; 8: 107-129
  CrossrefPubMedGoogle Scholar
• 12 Greenberg BD, Gabriels LA, Malone DA et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010; 15: 64-79
  Google Scholar
• 13 Greist JH, Bandelow B, Hollander E. World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 2003; 8: 7-16
  PubMedGoogle Scholar
• 14 Hesse S, Stengler K, Regenthal R, Patt M et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2011; 14: 606-617
  CrossrefPubMedGoogle Scholar
• 15 Hollander E, Koran LM, Goodman WK et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; (a) 64: 640-647
  CrossrefPubMedGoogle Scholar
• 16 Hollander E, Allen A, Steiner M et al. Paroxetine OCD Study Group. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003; (b) 64: 1113-1121
  CrossrefPubMedGoogle Scholar
• 17 Huppert JD, Franklin ME. Cognitive behavioral therapy for obsessive-compulsive disorder: an update. Curr Psychiatry Rep 2005; 7: 268-273
  CrossrefPubMedGoogle Scholar
• 18 Jenike MA, Baer L, Summergrad P et al. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989; 146: 1328-1330
  CrossrefPubMedGoogle Scholar
• 19 Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990; 28: 401-414
  CrossrefPubMedGoogle Scholar
• 20 Komossa K, Depping AM, Meyer M et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev 2010; 12 CD008141
  PubMedGoogle Scholar
• 21 Lesch KP, Osterheider M, Wiesmann M et al. Sensitivität des prä- und postsynaptischen 5-HT1A-Receptors bei Zwangskrankheit. In: Gaebel W, Laux G. Hrsg Biologische Psychiatrie. Berlin: Springer; 1992: 413-418
  CrossrefGoogle Scholar
• 22 Li X. Risperidone and Haloperidol augmentation of serotoninreuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005; 66: 736-743
  CrossrefPubMedGoogle Scholar
• 23 Lochner C, Stein DJ. Heterogeneity of obsessive-compulsive disorder: a literature review. Harv Rev Psychiatry 2003; 11: 113-132
  CrossrefPubMedGoogle Scholar
• 24 Mantovani A, Simpson HB, Fallon BA et al. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistent obsessive-compulsive disorder. Int J Neuropsychopharmacol 2010; 13: 217-227
  CrossrefPubMedGoogle Scholar
• 25 Matsunaga H, Nagata T, Hayashida K et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009; 70: 863-868
  CrossrefPubMedGoogle Scholar
• 26 Pallanti S, Hollander E, Bienstock C et al. International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181-191
  PubMedGoogle Scholar
• 27 Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004; 65: 6-10
  PubMedGoogle Scholar
• 28 Reynghe de Voxrie GV. Anafranil (G34586) in obsessive neurosis. Acta Neurol Psychiatr Belg 1968; 68: 787-792
  PubMedGoogle Scholar
• 29 Rodriguez-Martin JL, Barbanoj JM, Pérez V, Sacristan M. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev 2003; 3 CD003387
  PubMedGoogle Scholar
• 30 Rosenberg DR, Keshavan MS. Toward a neurodevelopmental model of of obsessive--compulsive disorder. Biol Psychiatry. 1998; 43: 623-640
  CrossrefPubMedGoogle Scholar
• 31 Soomro GM. Obsessive compulsive disorder. Clin Evid (Online) 2007; pii:1004
  PubMedGoogle Scholar
• 32 Stein DJ. Obsessive-compulsive disorder. Lancet 2002; 360: 397-405
  CrossrefPubMedGoogle Scholar
• 33 Stengler-Wenzke K, Müller U, Barthel H et al. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder. Neuropsychobiology 2006; 53: 40-45
  CrossrefPubMedGoogle Scholar
• 34 Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169: 468-474
  CrossrefPubMedGoogle Scholar